HM101207 / Hanmi - LARVOL DELTA

Breaking the KRAS inhibitor induced resistance-wall: Targeting KRAS-SOS1 to disarm hypoxic survival (AACR 2026) - "Significant progress has been made in targeting KRAS, however, KRAS G12C inhibitors like sotorasib and adagrasib have shown only modest efficacy with ORR of 28-43% and PFS of around 6 months, highlighting unmet needs for overcoming the resistance compared to EGFR inhibitors like osimertinib with ORR of 77% and PFS of 18.9 months...In NCI-H1373 and NCI-H2122 xenograft models, oral administration of HM101207 at 100 mg/kg produced a marked enhancement of antitumor activity when combined with adagrasib at low dose 20 mg/kg and high dose 100 mg/kg, or with RMC-6236 25 mg/kg...As a combination therapy, it enables more durable pathway inhibition and enhanced antitumor efficacy. GLP toxicology studies are ongoing to support IND submission."

Oncology • KRAS • MKNK2 • NRAS • PFKFB3 • PGK1 • PI3K • SERPINE1 • SLC2A1 • SOS1

Discovery of a novel SOS1-KRASmulti inhibitor, HM101207, demonstrates a broad-spectrum antitumor activity across KRAS-MAPK mutant cancers (AACR 2025) - "Preclinical studies have shown that HM101207 may overcome existing limitations of KRAS G12C or MEK inhibitors through combination strategy. HM101207 is currently preparing in IND enabling GLP-toxicity studies to support further clinical development."

Late-breaking abstract • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • NF1 • PTPN11

SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors (AACR-NCI-EORTC 2025) - "And it has the potential to overcome the limitations of KRAS-MAPK pathway inhibitors through combination. Currently, HM101207 is undergoing GLP toxicology studies for IND submission."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Hanmi Pharmaceutical Presents the Most Research Outcomes at AACR, Innovating Beyond Obesity to Cancer Treatment (Korea IT Times) - "Hanmi Pharmaceutical has announced that it will present the highest number of research outcomes among domestic pharmaceutical and bio companies at the prestigious American Association for Cancer Research (AACR) for three consecutive years, demonstrating the future value of its cancer drug pipeline."

Preclinical • Oncology